drugset

drugset / Trial / NCT07235059

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease

NCT07235059 ↗

Phase 1 Recruiting 112 enrolled Novartis Pharmaceuticals

RandomizedSequentialDouble-blindTreatment

Summary

The purpose of this first-in-human (FIH) study is to evaluate safety, tolerability, pharmacokinetic (PK) of OJR520.

Timeline

Start: 2025-11-20
Primary completion: 2028-01-21
Completion: 2028-01-21

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	OJR520	Unknown	—	—

Indications